AMAG Pharmaceuticals, Inc. (AMAG) has appointed Robert J. Perez to its board of directors. Perez is presently the executive vice president and chief operating officer at Cubist Pharmaceuticals, Inc (Cubist). In his role at Cubist, Perez is responsible for commercial operations, business development, technical operations, the Cubicin (daptomycin for injection) development team and information technology.
Perez comes to Cubist in 2003 as senior vice president, sales and marketing, and led the launch of Cubicin.
“Rob’s commercial and operational experience will be particularly helpful to us as we plan for the successful launch of Feraheme(TM),” commented Brian J.G. Pereira, president and chief executive officer of AMAG Pharmaceuticals, Inc. “With over twenty years of pharmaceutical experience, Rob’s wealth of knowledge and expertise will be a valuable addition to our Board,” concluded Pereira.
Prior to joining Cubist, Perez spent about nine years at Biogen, Inc. where he held several management positions. From 2001 to 2003, he served as the vice president-CNS Business Unit, where he was responsible for the commercial leadership of an $800 million neurology business unit and from 1995 to 2001, held positions of increasing responsibility within the commercial organization. From 1987 to 1995, Perez held various sales and marketing positions at Zeneca Pharmaceuticals.
Perez holds an MBA from The Anderson School at UCLA and a BS from California State University, Los Angeles.